SLR HC BDC 10-Q 6 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	SLR HC BDC LLC
Entity Central Index Key	0001832148
Securities Act File Number	814-01382
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Transition Report	false
Document Quarterly Report	true
Entity Tax Identification Number	85-1801692
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	500 Park Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	212
Local Phone Number	993-1670
Entity Common Stock, Shares Outstanding		1,185,276

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands		Sep. 30, 2024		Dec. 31, 2023
Investments at fair value:
Cash		$ 2,614		$ 1,871
Cash equivalents (cost: $0 and $9,919, respectively)		0		9,919
Interest receivable		573		503
Dividends receivable		1		0
Receivable for investments sold		28		0
Prepaid expenses		6		14
Total assets		75,844		75,582
Liabilities
Payable for cash equivalents purchased		0		9,919
Management fee payable (see note 3)		301		524
Incentive fee payable (see note 3)		447		0
Administration fee payable (see note 3)		14		12
Interest payable (see note 5)		715		904
Other liabilities and accrued expenses		168		231
Total liabilities		49,727		52,613
Commitments and contingencies (see note 6)
Unitholders' Capital
Common Unitholders' capital (1,185,276 and 1,069,642 units, respectively, issued and outstanding)		25,893		23,393
Accumulated distributable net earnings (loss)		224		(424)
Total unitholders' capital		26,117	[1],[2]	22,969
Total liabilities and unitholders' capital		$ 75,844		$ 75,582
Net asset value per unit	[3]	$ 22.03		$ 21.47
Non Controlled Non Affiliated Investments [Member]
Investments at fair value:
Non-controlled/non-affiliated investments (cost: $71,562 and $62,743, respectively)		$ 72,622		$ 63,275
Revolving Credit Facility Due February Two Thousand And Twenty Seven the SPV Facility [Member]
Liabilities
Long-Term Line of Credit		25,443		23,501
Revolving Credit Facility Due March Two Thousand and Twenty Five the Subscription Facility [Member]
Liabilities
Long-Term Line of Credit		$ 22,639		$ 17,522
[1] Calculated as the change in net asset value (“NAV”) per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. Not annualized for periods less than one year. Calculated using the average units outstanding method. Weighted average units outstanding for the nine months ended September 30, 2024 and September 30, 2023 were 1,113,111 and 1,015,916 , respectively.

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investment owned, at Cost		$ 72,662
Cash equivalents, at Cost	$ 0	$ 9,919
Common unit, Issued	1,185,276	1,069,642
Common unit, Outstanding	1,185,276	1,069,642
Revolving Credit Facility Due February Two Thousand And Twenty Seven the SPV Facility [Member]
Long term debt, Gross	$ 25,980	$ 24,210
Debt issuance costs, Line of credit arrangements, Gross	537	709
Revolving Credit Facility Due March Two Thousand and Twenty Five the Subscription Facility [Member]
Long term debt, Gross	22,700	17,550
Debt issuance costs, Line of credit arrangements, Gross	61	28
Non Controlled Non Affiliated Investments [Member]
Investment owned, at Cost	$ 71,562	$ 62,743

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investment Income:
Total investment income	$ 2,324	$ 1,719	$ 6,549	$ 4,821
Expenses:
Management fees (see note 3)	186	143	507	408
Incentive fees (see note 3)	447	0	447	0
Administration fees (see note 3)	14	10	39	30
Interest and other credit facility expenses (see note 5)	1,114	1,106	3,229	2,854
Other general and administrative expenses	120	177	461	561
Total expenses	1,881	1,436	4,683	3,853
Net investment income	443	283	1,866	968
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized gain (loss) on non-controlled/non-affiliated investments and cash equivalents	6	(2)	2	(17)
Net change in unrealized gain (loss) on non-controlled/non-affiliated investments and cash equivalents	598	129	528	188
Net realized and unrealized gain (loss) on non-controlled/non-affiliated investments and cash equivalents	604	127	530	171
Net increase in unitholders' capital resulting from operations	$ 1,047	$ 410	$ 2,396	$ 1,139
Net Income Per Unit	$ 0.88	$ 0.38	$ 2.15	$ 1.12
Investments and cash equivalents [Member]
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized gain (loss) on non-controlled/non-affiliated investments and cash equivalents			$ 2	$ (17)
Net change in unrealized gain (loss) on non-controlled/non-affiliated investments and cash equivalents	$ 598	$ 129	528	188
Non Controlled Non Affiliated Investments [Member]
Investment Income:
Interest income from non-controlled/non-affiliated investments	2,224	1,702	6,437	4,795
Dividend income from non-controlled/non-affiliated investments	8	0	8	0
Other income from non-controlled/non-affiliated investments	92	17	104	26
Realized and unrealized gain (loss) on investments and cash equivalents:
Net realized gain (loss) on non-controlled/non-affiliated investments and cash equivalents	$ 6	$ (2)	$ 2	$ (17)

Consolidated Statements of Chan

Consolidated Statements of Changes in Unitholders' Capital - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Increase (decrease) in unitholders' capital resulting from operations:
Net investment income	$ 443	$ 283	$ 1,866	$ 968
Net realized gain (loss)	6	(2)	2	(17)
Net change in unrealized gain (loss)	598	129	528	188
Net increase in unitholders' capital resulting from operations	1,047	410	2,396	1,139
Distributions to unitholders:
From distributable earnings	(608)	(540)	(1,748)	(1,422)
Increase in unitholders' capital resulting from capital activity:
Contributions	0	0	2,500	4,000
Net increase in unitholders' capital resulting from capital activity	0	0	2,500	4,000
Total increase (decrease) in unitholders' capital	439	(130)	3,148	3,717
Unitholders' capital, beginning of period	25,678	23,195	22,969	19,348
Unitholders' capital, end of period	$ 26,117	$ 23,065	$ 26,117	$ 23,065
Capital unit activity (see note 7):
Units issued	0	0	115,634	181,077
Net increase from capital unit activity	0	0	115,634	181,077

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net increase in unitholders' capital resulting from operations	$ 2,396	$ 1,139
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash provided by (used in) operating activities:
Net realized (gain) loss on investments and cash equivalents	(2)	17
Deferred financing costs amortization	279	247
Net accretion of discount on investments	(364)	(351)
(Increase) decrease in operating assets:
Purchase of investments	(14,421)	(15,118)
Proceeds from disposition of investments	6,225	5,507
Capitalization of payment-in-kind income	(257)	(298)
Interest receivable	(70)	(161)
Dividends receivable	(1)	0
Prepaid expenses	8	(20)
Receivable for investments sold	(28)	(11)
Increase (decrease) in operating liabilities:
Payable for cash equivalents purchased	(9,919)	(17,915)
Management fee payable	(223)	42
Incentive fee payable	447	0
Administration fee payable	2	3
Interest payable	(189)	341
Other liabilities and accrued expenses	(63)	34
Net Cash Used in Operating Activities	(16,708)	(26,732)
Cash Flows from Financing Activities:
Contributions from unitholders	2,500	4,000
Cash distributions paid	(1,748)	(1,422)
Proceeds from borrowings	21,530	16,289
Repayments of borrowings	(14,750)	(11,750)
Net Cash Provided by Financing Activities	7,532	7,117
NET DECREASE IN CASH AND CASH EQUIVALENTS	(9,176)	(19,615)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	11,790	33,814
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2,614	14,199
Supplemental disclosure of cash flow information:
Cash paid for interest	3,139	2,513
Non-cash purchase and disposition of investments	2,456	0
Investments and cash equivalents [Member]
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash provided by (used in) operating activities:
Net realized (gain) loss on investments and cash equivalents	(2)	17
Investments [Member]
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash provided by (used in) operating activities:
Net change in unrealized (gain) loss on investments	$ (528)	$ (188)

Consolidated Schedule of Invest

Consolidated Schedule of Investments - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2024		Dec. 31, 2023
Schedule of Investments [Line Items]
Cost				$ 72,662
Investments Cash and Cash Equivalents at Fair Value.				73,194
Liabilities in Excess of Other Assets		$ (46,505)		(50,225)
Net Assets		$ 26,117		$ 22,969
Percentage Of Total Investments At Fair Value		100%		100%
Health Care Providers Services [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		52.20%		50.90%
Health Care Equipment Supplies [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		14.60%		16.10%
Pharmaceuticals [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		13.30%		12.70%
Diversified Consumer Services [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		5.70%
Life Sciences Tools Services [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		5.20%		6.30%
Biotechnology [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		4.60%		11.30%
Diversified Financial Services [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		2.60%
Distributors [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		1.10%		1.20%
Health Care Technology [Member]
Schedule of Investments [Line Items]
Percentage Of Total Investments At Fair Value		0.70%		1.50%
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans
Schedule of Investments [Line Items]
Cost		$ 69,092		$ 62,704
Fair Value		$ 69,998		$ 63,268
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | AAH Topco., LLC | Diversified Consumer Services | S+525 | 0.75% | 10.20% | 1/30/2024 | 12/22/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	525%
Floor	[2]	0.75%
Interest Rate	[2],[3]	10.20%
Investment, Acquisition Date	[2]	Jan. 30, 2024
Maturity Date	[2]	Dec. 22, 2027
Par Amount	[2]	$ 958
Cost	[2]	941
Fair Value	[2]	$ 958
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics, Inc | Pharmaceuticals | S+745 | 0.10% | 12.90% | 12/22/2021 | 1/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5],[6]			745%
Floor	[5],[6]			0.10%
Interest Rate	[5],[6],[7]			12.90%
Investment, Acquisition Date	[5],[6]			Dec. 22, 2021
Maturity Date	[5],[6]			Jan. 01, 2027
Par Amount	[5],[6]			$ 6,288
Cost	[5],[6]			6,422
Fair Value	[5],[6]			$ 6,414
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Arcutis Biotherapeutics, Inc. | Pharmaceuticals | S+595 | 2.50% | 11.12% | 12/22/2021 | 8/1/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2],[8]	595%
Floor	[2],[8]	2.50%
Interest Rate	[2],[3],[8]	11.12%
Investment, Acquisition Date	[2],[8]	Dec. 22, 2021
Maturity Date	[2],[8]	Aug. 01, 2029
Par Amount	[2],[8]	$ 6,288
Cost	[2],[8]	6,492
Fair Value	[2],[8]	$ 6,647
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ardelyx, Inc | Pharmaceuticals | S+795 | 1.00% | 13.32% | 2/23/2022 | 3/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5],[6]			795%
Floor	[5],[6]			1%
Interest Rate	[5],[6],[7]			13.32%
Investment, Acquisition Date	[5],[6]			Feb. 23, 2022
Maturity Date	[5],[6]			Mar. 01, 2027
Par Amount	[5],[6]			$ 1,548
Cost	[5],[6]			1,559
Fair Value	[5],[6]			$ 1,596
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Ardelyx, Inc. | Pharmaceuticals | S+425 | 4.70% | 9.45% | 2/23/2022 | 3/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2],[8]	425%
Floor	[2],[8]	4.70%
Interest Rate	[2],[3],[8],[9]	9.45%
Investment, Acquisition Date	[2],[8]	Feb. 23, 2022
Maturity Date	[2],[8]	Mar. 01, 2027
Par Amount	[2],[8]	$ 2,893
Cost	[2],[8]	2,927
Fair Value	[2],[8]	$ 2,979
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BayMark Health Services, Inc | Health Care Providers & Services | S+500 | 1.00% | 10.61% | 6/29/2021 | 6/11/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			500%
Floor	[5]			1%
Interest Rate	[5],[7]			10.61%
Investment, Acquisition Date	[5]			Jun. 29, 2021
Maturity Date	[5]			Jun. 11, 2027
Par Amount	[5]			$ 4,026
Cost	[5]			4,000
Fair Value	[5]			$ 4,026
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BayMark Health Services, Inc. | Health Care Providers & Services | S+500 | 1.00% | 9.87% | 6/29/2021 | 6/11/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	500%
Floor	[2]	1%
Interest Rate	[2],[3]	9.87%
Investment, Acquisition Date	[2]	Jun. 29, 2021
Maturity Date	[2]	Jun. 11, 2027
Par Amount	[2]	$ 3,995
Cost	[2]	3,975
Fair Value	[2]	$ 3,995
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | BridgeBio Pharma, Inc | Biotechnology | 9.00% | 11/17/2021 | 11/17/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5],[6]			0%
Floor	[5],[6]			0%
Interest Rate	[5],[6],[7],[10]			9%
Investment, Acquisition Date	[5],[6]			Nov. 17, 2021
Maturity Date	[5],[6]			Nov. 17, 2026
Par Amount	[5],[6]			$ 3,767
Cost	[5],[6]			3,765
Fair Value	[5],[6]			$ 3,777
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | CVAUSA Management, LLC | Health Care Providers & Services | S+650 | 1.00% | 11.12% | 5/22/2023 | 5/22/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.12%
Investment, Acquisition Date	[2]	May 22, 2023
Maturity Date	[2]	May 22, 2029
Par Amount	[2]	$ 1,679
Cost	[2]	1,636
Fair Value	[2]	$ 1,679
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | CVAUSA Management, LLC.| Health Care Providers & Services | S+650 | 1.00% | 11.74% | 5/22/2023 | 5/22/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			650%
Floor	[5]			1%
Interest Rate	[5],[7]			11.74%
Investment, Acquisition Date	[5]			May 22, 2023
Maturity Date	[5]			May 22, 2029
Par Amount	[5]			$ 1,691
Cost	[5]			1,643
Fair Value	[5]			$ 1,691
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Cerapedics Inc. | Biotechnology | S+620 | 2.75% | 11.37% | 12/27/2022 | 1/1/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	620%
Floor	[2]	2.75%
Interest Rate	[2],[3]	11.37%
Investment, Acquisition Date	[2]	Dec. 27, 2022
Maturity Date	[2]	Jan. 01, 2028
Par Amount	[2]	$ 3,348
Cost	[2]	3,374
Fair Value	[2]	$ 3,364
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Cerapedics Inc.| Biotechnology | S+620 | 2.75% | 11.55% | 12/27/2022 | 1/1/2028
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			620%
Floor	[5]			2.75%
Interest Rate	[5],[7]			11.55%
Investment, Acquisition Date	[5]			Dec. 27, 2022
Maturity Date	[5]			Jan. 01, 2028
Par Amount	[5]			$ 3,348
Cost	[5]			3,357
Fair Value	[5]			$ 3,348
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Exactcare Parent, Inc. | Health Care Providers & Services | S+550 | 1.00% | 10.73% | 11/3/2023 | 11/5/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	1%
Interest Rate	[2],[3]	10.73%
Investment, Acquisition Date	[2]	Nov. 03, 2023
Maturity Date	[2]	Nov. 05, 2029
Par Amount	[2]	$ 929
Cost	[2]	906
Fair Value	[2]	$ 929
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Exactcare Parent, Inc.| Health Care Providers & Services | S+650 | 1.00% | 11.89% | 11/3/2023 | 11/5/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			650%
Floor	[5]			1%
Interest Rate	[5],[7]			11.89%
Investment, Acquisition Date	[5]			Nov. 03, 2023
Maturity Date	[5]			Nov. 05, 2029
Par Amount	[5]			$ 934
Cost	[5]			909
Fair Value	[5]			$ 908
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Eyesouth Eye Care Holdco LLC | Health Care Providers & Services | S+550 | 1.00% | 10.45% | 10/6/2022 | 10/5/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	1%
Interest Rate	[2],[3]	10.45%
Investment, Acquisition Date	[2]	Oct. 06, 2022
Maturity Date	[2]	Oct. 05, 2029
Par Amount	[2]	$ 3,170
Cost	[2]	3,088
Fair Value	[2]	$ 3,170
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | FE Advance, LLC | Diversified Consumer Services | S+650 | 1.00% | 11.71% | 7/30/2024 | 7/30/2027
Schedule of Investments [Line Items]
Spread above Index	[1]	650%
Floor		1%
Interest Rate	[3]	11.71%
Investment, Acquisition Date		Jul. 30, 2024
Maturity Date		Jul. 30, 2027
Par Amount		$ 1,956
Cost		1,918
Fair Value		$ 1,916
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco, LLC | Health Care Providers & Services | S+650 | 1.00% | 11.74% | 1/4/2023 | 1/3/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.74%
Investment, Acquisition Date	[2]	Jan. 04, 2023
Maturity Date	[2]	Jan. 03, 2029
Par Amount	[2]	$ 2,624
Cost	[2]	2,562
Fair Value	[2]	$ 2,624
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Fertility (ITC) Investment Holdco, LLC.| Health Care Providers & Services | S+650 | 1.00% | 11.97% | 1/4/2023 | 1/3/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			650%
Floor	[5]			1%
Interest Rate	[5],[7]			11.97%
Investment, Acquisition Date	[5]			Jan. 04, 2023
Maturity Date	[5]			Jan. 03, 2029
Par Amount	[5]			$ 2,643
Cost	[5]			2,574
Fair Value	[5]			$ 2,643
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Glooko, Inc. | Health Care Providers & Services | S+790 | 0.10% | 13.35% | 9/30/2021 | 10/1/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			790%
Floor	[5]			0.10%
Interest Rate	[5],[7]			13.35%
Investment, Acquisition Date	[5]			Sep. 30, 2021
Maturity Date	[5]			Oct. 01, 2026
Par Amount	[5]			$ 907
Cost	[5]			919
Fair Value	[5]			$ 948
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Maxor Acquisition, Inc. | Health Care Providers & Services | S+675 | 1.00% | 11.70% | 3/1/2023 | 3/1/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	675%
Floor	[2]	1%
Interest Rate	[2],[3]	11.70%
Investment, Acquisition Date	[2]	Mar. 01, 2023
Maturity Date	[2]	Mar. 01, 2029
Par Amount	[2]	$ 1,748
Cost	[2]	1,706
Fair Value	[2]	$ 1,748
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Maxor Acquisition, Inc.. | Health Care Providers & Services | S+675 | 1.00% | 12.48% | 3/1/2023 | 3/1/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			675%
Floor	[5]			1%
Interest Rate	[5],[7]			12.48%
Investment, Acquisition Date	[5]			Mar. 01, 2023
Maturity Date	[5]			Mar. 01, 2029
Par Amount	[5]			$ 1,761
Cost	[5]			1,714
Fair Value	[5]			$ 1,761
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Meditrina, Inc. | Health Care Equipment & Supplies | S+550 | 3.45% | 10.85% |12/20/2022 | 12/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			550%
Floor	[5]			3.45%
Interest Rate	[5],[7]			10.85%
Investment, Acquisition Date	[5]			Dec. 20, 2022
Maturity Date	[5]			Dec. 01, 2027
Par Amount	[5]			$ 312
Cost	[5]			313
Fair Value	[5]			$ 315
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Meditrina, Inc. | Health Care Providers & Services | S+550 | 3.45% | 10.67% | 12/20/2022 | 12/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	3.45%
Interest Rate	[2],[3]	10.67%
Investment, Acquisition Date	[2]	Dec. 20, 2022
Maturity Date	[2]	Dec. 01, 2027
Par Amount	[2]	$ 468
Cost	[2]	472
Fair Value	[2]	$ 472
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+600 | 1.00% | 11.55% | 10/20/2023 | 10/20/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	600%
Floor	[2]	1%
Interest Rate	[2],[3]	11.55%
Investment, Acquisition Date	[2]	Oct. 20, 2023
Maturity Date	[2]	Oct. 20, 2029
Par Amount	[2]	$ 692
Cost	[2]	677
Fair Value	[2]	$ 692
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Medrina, LLC | Health Care Providers & Services | S+625| 1.00% | 11.67% | 10/20/2023 | 10/20/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			625%
Floor	[5]			1%
Interest Rate	[5],[7]			11.67%
Investment, Acquisition Date	[5]			Oct. 20, 2023
Maturity Date	[5]			Oct. 20, 2029
Par Amount	[5]			$ 697
Cost	[5]			680
Fair Value	[5]			$ 680
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+475 | 0.75% | 9.35% | 12/29/2023 | 11/16/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	475%
Floor	[2]	0.75%
Interest Rate	[2],[3]	9.35%
Investment, Acquisition Date	[2]	Dec. 29, 2023
Maturity Date	[2]	Nov. 16, 2028
Par Amount	[2]	$ 2,739
Cost	[2]	2,698
Fair Value	[2]	$ 2,711
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | OIS Management Services, LLC | Health Care Providers & Services | S+575 | 0.75% | 11.20% |12/29/2023 | 11/16/2028
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			575%
Floor	[5]			0.75%
Interest Rate	[5],[7]			11.20%
Investment, Acquisition Date	[5]			Dec. 29, 2023
Maturity Date	[5]			Nov. 16, 2028
Par Amount	[5]			$ 875
Cost	[5]			868
Fair Value	[5]			$ 858
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | ONS MSO, LLC | Health Care Providers & Services | S+575 | 1.00% | 10.60% | 4/26/2024 | 7/8/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	575%
Floor	[2]	1%
Interest Rate	[2],[3]	10.60%
Investment, Acquisition Date	[2]	Apr. 26, 2024
Maturity Date	[2]	Jul. 08, 2026
Par Amount	[2]	$ 869
Cost	[2]	862
Fair Value	[2]	$ 869
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | ONS MSO, LLC | Health Care Providers & Services | S+625 | 1.00% | 11.35% | 2/10/2023 | 7/8/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11.35%
Investment, Acquisition Date	[2]	Feb. 10, 2023
Maturity Date	[2]	Jul. 08, 2026
Par Amount	[2]	$ 2,502
Cost	[2]	2,455
Fair Value	[2]	$ 2,502
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management, LLC | Health Care Providers & Services | S+650 | 1.00% | 11.46% | 8/17/2022 | 11/15/2024
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.46%
Investment, Acquisition Date	[2]	Aug. 17, 2022
Maturity Date	[2]	Nov. 15, 2024
Par Amount	[2]	$ 2,269
Cost	[2]	2,266
Fair Value	[2]	$ 2,269
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Orthopedic Care Partners Management, LLC | Health Care Providers & Services | S+650 | 1.00% | 12.11% | 8/17/2022 | 5/16/2024
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			650%
Floor	[5]			1%
Interest Rate	[5],[7]			12.11%
Investment, Acquisition Date	[5]			Aug. 17, 2022
Maturity Date	[5]			May 16, 2024
Par Amount	[5]			$ 1,673
Cost	[5]			1,669
Fair Value	[5]			$ 1,673
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Outset Medical, Inc | Health Care Equipment & Supplies | S+515 | 2.75% | 10.50% | 11/3/2022 | 11/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5],[6]			515%
Floor	[5],[6]			2.75%
Interest Rate	[5],[6],[7]			10.50%
Investment, Acquisition Date	[5]			Nov. 03, 2022
Maturity Date	[5],[6]			Nov. 01, 2027
Par Amount	[5],[6]			$ 3,909
Cost	[5],[6]			3,918
Fair Value	[5],[6]			$ 3,918
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Outset Medical, Inc. | Health Care Providers & Services | S+515 | 2.75% | 10.32% | 11/3/2022 | 11/1/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	515%
Floor	[2]	2.75%
Interest Rate	[2],[3]	10.32%
Investment, Acquisition Date	[2]	Nov. 03, 2022
Maturity Date	[2]	Nov. 01, 2027
Par Amount	[2]	$ 3,909
Cost	[2]	3,952
Fair Value	[2]	$ 4,134
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Plastic Management, LLC | Health Care Providers & Services | S+500 | 1.00% | 10.45% | 8/26/2021 | 8/18/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			500%
Floor	[5]			1%
Interest Rate	[5],[7]			10.45%
Investment, Acquisition Date	[5]			Aug. 26, 2021
Maturity Date	[5]			Aug. 18, 2027
Par Amount	[5]			$ 3,861
Cost	[5]			3,824
Fair Value	[5]			$ 3,861
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Plastic Management, LLC | Health Care Providers & Services | S+500 | 1.00% | 9.70% | 8/26/2021 | 8/18/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	500%
Floor	[2]	1%
Interest Rate	[2],[3]	9.70%
Investment, Acquisition Date	[2]	Aug. 26, 2021
Maturity Date	[2]	Aug. 18, 2027
Par Amount	[2]	$ 3,832
Cost	[2]	3,802
Fair Value	[2]	$ 3,832
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | RQM+ Corp | Life Sciences Tools & Services | S+575 | 1.00% | 10.62% | 8/20/2021 | 8/12/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	575%
Floor	[2]	1%
Interest Rate	[2],[3]	10.62%
Investment, Acquisition Date	[2]	Aug. 20, 2021
Maturity Date	[2]	Aug. 12, 2026
Par Amount	[2]	$ 3,961
Cost	[2]	3,936
Fair Value	[2]	$ 3,803
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | RQM+ Corp. | Life Sciences Tools & Services | S+575 | 1.00% | 11.36% | 8/20/2021 | 8/12/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			575%
Floor	[5]			1%
Interest Rate	[5],[7]			11.36%
Investment, Acquisition Date	[5]			Aug. 20, 2021
Maturity Date	[5]			Aug. 12, 2026
Par Amount	[5]			$ 3,992
Cost	[5]			3,957
Fair Value	[5]			$ 3,992
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Retina Midco, Inc. | Health Care Providers & Services | S+575 | 1.00% | 10.86% | 12/18/2023 | 1/31/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	575%
Floor	[2]	1%
Interest Rate	[2],[3]	10.86%
Investment, Acquisition Date	[2]	Dec. 18, 2023
Maturity Date	[2]	Jan. 31, 2026
Par Amount	[2]	$ 3,841
Cost	[2]	3,787
Fair Value	[2]	$ 3,841
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Retina Midco, Inc. | Health Care Providers & Services | S+575 | 1.00% | 11.38% | 12/18/2023 | 1/31/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			575%
Floor	[5]			1%
Interest Rate	[5],[7]			11.38%
Investment, Acquisition Date	[5]			Dec. 18, 2023
Maturity Date	[5]			Jan. 31, 2026
Par Amount	[5]			$ 2,897
Cost	[5]			2,840
Fair Value	[5]			$ 2,839
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SCP Eye Care, LLC | Health Care Providers & Services | S+575 | 1.00% | 11.19% | 10/6/2022 | 10/5/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			575%
Floor	[5]			1%
Interest Rate	[5],[7]			11.19%
Investment, Acquisition Date	[5]			Oct. 06, 2022
Maturity Date	[5]			Oct. 05, 2029
Par Amount	[5]			$ 3,499
Cost	[5]			3,399
Fair Value	[5]			$ 3,499
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SPR Therapeutics, Inc. | Health Care Technology | S+515 | 4.00% | 10.32% | 1/30/2024 | 2/1/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	515%
Floor	[2]	4%
Interest Rate	[2],[3]	10.32%
Investment, Acquisition Date	[2]	Jan. 30, 2024
Maturity Date	[2]	Feb. 01, 2029
Par Amount	[2]	$ 501
Cost	[2]	500
Fair Value	[2]	$ 516
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management, LLC | Health Care Providers & Services | S+550 | 1.00% | 10.10% | 6/3/2022 | 7/27/2026
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	1%
Interest Rate	[2],[3]	10.10%
Investment, Acquisition Date	[2]	Jun. 03, 2022
Maturity Date	[2]	Jul. 27, 2026
Par Amount	[2]	$ 3,452
Cost	[2]	3,410
Fair Value	[2]	$ 3,452
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Southern Orthodontic Partners Management, LLC | Health Care Providers & Services | S+625 | 1.00% | 11.72% | 6/3/2022 | 1/27/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			625%
Floor	[5]			1%
Interest Rate	[5],[7]			11.72%
Investment, Acquisition Date	[5]			Jun. 03, 2022
Maturity Date	[5]			Jan. 27, 2026
Par Amount	[5]			$ 2,075
Cost	[5]			2,050
Fair Value	[5]			$ 2,075
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | SunMed Group Holdings, LLC | Health Care Equipment & Supplies | S+550 | 0.75% | 10.46% | 6/16/2021 | 6/16/2028
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	0.75%
Interest Rate	[2],[3]	10.46%
Investment, Acquisition Date	[2]	Jun. 16, 2021
Maturity Date	[2]	Jun. 16, 2028
Par Amount	[2]	$ 2,067
Cost	[2]	2,047
Fair Value	[2]	$ 2,067
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | UVP Management, LLC | Health Care Providers & Services | S+625 | 1.00% | 11.00% | 9/18/2023 | 9/15/2025
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	1%
Interest Rate	[2],[3]	11%
Investment, Acquisition Date	[2]	Sep. 18, 2023
Maturity Date	[2]	Sep. 15, 2025
Par Amount	[2]	$ 1,409
Cost	[2]	1,390
Fair Value	[2]	$ 1,409
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | UVP Management, LLC| Health Care Providers & Services | S+625 | 1.00% | 11.75% | 9/18/2023 | 9/15/2025
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			625%
Floor	[5]			1%
Interest Rate	[5],[7]			11.75%
Investment, Acquisition Date	[5]			Sep. 18, 2023
Maturity Date	[5]			Sep. 15, 2025
Par Amount	[5]			$ 1,285
Cost	[5]			1,257
Fair Value	[5]			$ 1,253
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | United Digestive MSO Parent, LLC | Health Care Providers & Services | S+650 | 1.00% | 11.25% | 3/30/2023 | 3/30/2029
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	650%
Floor	[2]	1%
Interest Rate	[2],[3]	11.25%
Investment, Acquisition Date	[2]	Mar. 30, 2023
Maturity Date	[2]	Mar. 30, 2029
Par Amount	[2]	$ 1,001
Cost	[2]	976
Fair Value	[2]	$ 1,001
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | United Digestive MSO Parent, LLC | Health Care Providers & Services | S+675 | 1.00% | 12.25% | 3/30/2023 | 3/30/2029
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			675%
Floor	[5]			1%
Interest Rate	[5],[7]			12.25%
Investment, Acquisition Date	[5]			Mar. 30, 2023
Maturity Date	[5]			Mar. 30, 2029
Par Amount	[5]			$ 982
Cost	[5]			955
Fair Value	[5]			$ 982
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Urology Management Holdings, Inc. | Health Care Providers & Services | S+550 | 1.00% | 10.52% | 2/7/2023 | 6/15/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	550%
Floor	[2]	1%
Interest Rate	[2],[3]	10.52%
Investment, Acquisition Date	[2]	Feb. 07, 2023
Maturity Date	[2]	Jun. 15, 2027
Par Amount	[2]	$ 1,106
Cost	[2]	1,083
Fair Value	[2]	$ 1,095
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Urology Management Holdings, Inc. | Health Care Providers & Services | S+650 | 1.00% | 11.93% | 2/7/2023 | 6/15/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			650%
Floor	[5]			1%
Interest Rate	[5],[7]			11.93%
Investment, Acquisition Date	[5]			Feb. 07, 2023
Maturity Date	[5]			Jun. 15, 2026
Par Amount	[5]			$ 920
Cost	[5]			897
Fair Value	[5]			$ 913
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vapotherm, Inc. | Health Care Equipment & Supplies | S+600 | 4.50% | 10.96% | 2/18/2022 | 9/20/2027
Schedule of Investments [Line Items]
Spread above Index	[1]	600%
Floor		4.50%
Interest Rate	[3]	10.96%
Investment, Acquisition Date		Feb. 18, 2022
Maturity Date		Sep. 20, 2027
Par Amount		$ 1,238
Cost		1,269
Fair Value		$ 1,276
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vapotherm, Inc.| Health Care Equipment & Supplies | S+930 | 1.00% | 14.75% | 2/18/2022 | 2/1/2027
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			930%
Floor	[5]			1%
Interest Rate	[5],[7],[11]			14.75%
Investment, Acquisition Date	[5]			Feb. 18, 2022
Maturity Date	[5]			Feb. 01, 2027
Par Amount	[5]			$ 3,384
Cost	[5]			3,437
Fair Value	[5]			$ 3,435
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Vertos Medical, Inc.| Health Care Equipment & Supplies | S+515 | 4.75% | 10.50% | 6/14/2023 | 7/1/2028
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			515%
Floor	[5]			4.75%
Interest Rate	[5],[7]			10.50%
Investment, Acquisition Date	[5]			Jun. 14, 2023
Maturity Date	[5]			Jul. 01, 2028
Par Amount	[5]			$ 567
Cost	[5]			563
Fair Value	[5]			$ 567
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+625 | 0.75% | 11.48% | 11/6/2023 | 11/6/2030
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	625%
Floor	[2]	0.75%
Interest Rate	[2],[3]	11.48%
Investment, Acquisition Date	[2]	Nov. 06, 2023
Maturity Date	[2]	Nov. 06, 2030
Par Amount	[2]	$ 834
Cost	[2]	815
Fair Value	[2]	$ 834
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | WCI-BXC Purchaser, LLC | Distributors | S+625 | 1.00% | 11.64% | 11/6/2023 | 11/6/2030
Schedule of Investments [Line Items]
Spread above Index	[4]			625%
Floor				1%
Interest Rate	[7]			11.64%
Investment, Acquisition Date	[5]			Nov. 06, 2023
Maturity Date				Nov. 06, 2030
Par Amount				$ 840
Cost				820
Fair Value				$ 819
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans | Western Veterinary Partners LLC | Diversified Consumer Services | S+500 | 1.00% | 9.60% | 1/19/2024 | 10/29/2027
Schedule of Investments [Line Items]
Spread above Index	[1],[2]	500%
Floor	[2]	1%
Interest Rate	[2],[3]	9.60%
Investment, Acquisition Date	[2]	Jan. 19, 2024
Maturity Date	[2]	Oct. 29, 2027
Par Amount	[2]	$ 3,214
Cost	[2]	3,170
Fair Value	[2]	$ 3,214
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans |ONS MSO, LLC | Health Care Providers & Services | S+625 | 1.00% | 11.62% | 2/10/2023 | 7/8/2026
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			625%
Floor	[5]			1%
Interest Rate	[5],[7]			11.62%
Investment, Acquisition Date	[5]			Feb. 10, 2023
Maturity Date	[5]			Jul. 08, 2026
Par Amount	[5]			$ 2,527
Cost	[5]			2,469
Fair Value	[5]			$ 2,527
Investment, Identifier [Axis]: Bank Debt/Senior Secured Loans |SunMed Group Holdings, LLC | Health Care Equipment & Supplies | S+550 | 0.75% | 10.96% | 6/16/2021 | 6/16/2028
Schedule of Investments [Line Items]
Spread above Index	[4],[5]			550%
Floor	[5]			0.75%
Interest Rate	[5],[7]			10.96%
Investment, Acquisition Date	[5]			Jun. 16, 2021
Maturity Date	[5]			Jun. 16, 2028
Par Amount	[5]			$ 1,950
Cost	[5]			1,926
Fair Value	[5]			$ 1,950
Investment, Identifier [Axis]: Cash Equivalents | US Treasury Bill | Government | 12/29/2023 | 2/27/2024
Schedule of Investments [Line Items]
Investment, Acquisition Date				Feb. 27, 2024
Maturity Date				Dec. 29, 2023
Par Amount				$ 10,000
Cost				9,919
Fair Value				$ 9,919
Investment, Identifier [Axis]: Common Equity/Warrants | Assertio Holdings Inc Common Stock | Pharmaceuticals | 7/31/2023
Schedule of Investments [Line Items]
Maturity Date		Jul. 31, 2023		Jul. 31, 2023	[12],[13]
Par Amount		$ 1,088	[14],[15]	$ 1,088	[12],[13]
Cost		4	[14],[15]	4	[12],[13]
Fair Value		$ 1	[14],[15]	1
Investment, Identifier [Axis]: Preferred Equity | Veronica Holdings,LLC (Vapotherm) | Health Care Equipment & Supplies | 9.00%PIK | 9/20/2024
Schedule of Investments [Line Items]
Interest Rate, PIK		9%
Maturity Date		Sep. 20, 2024
Par Amount	[15]	$ 1,172,897
Cost	[15]	2,433
Fair Value	[15]	2,563
Investment, Identifier [Axis]: Total Investments
Schedule of Investments [Line Items]
Cost		71,562	[16]	62,743	[17]
Fair Value		72,622	[16]	63,275
Investment, Identifier [Axis]: Total Preferred Equity
Schedule of Investments [Line Items]
Cost		2,433
Fair Value		2,563
Investment, Identifier [Axis]: Total Warrant
Schedule of Investments [Line Items]
Cost		37		39
Fair Value		$ 61		$ 7
Investment, Identifier [Axis]: Warrants | Meditrina Inc. | Health Care Equipment & Supplies | 12/20/2022
Schedule of Investments [Line Items]
Maturity Date		Dec. 20, 2022		Dec. 20, 2022	[13]
Par Amount		$ 4,079	[15]	$ 2,719	[13]
Cost		3	[15]	2	[13]
Fair Value		$ 3	[15]	$ 2
Investment, Identifier [Axis]: Warrants | Vapotherm Inc. | Health Care Equipment & Supplies | 2/18/2022
Schedule of Investments [Line Items]
Maturity Date	[13]			Feb. 18, 2022
Par Amount	[13]			$ 7,029
Cost	[13]			29
Fair Value				$ 0
Investment, Identifier [Axis]: Warrants | Veronica Holdings, LLC (Vapotherm) | Health Care Equipment & Supplies | 9/20/2024
Schedule of Investments [Line Items]
Maturity Date		Sep. 20, 2024
Par Amount	[15]	$ 26,336
Cost	[15]	30
Fair Value	[15]	$ 57
Investment, Identifier [Axis]: Warrants | Vertos Medical, Inc. | Health Care Equipment & Supplies | 6/14/2023
Schedule of Investments [Line Items]
Maturity Date	[13]			Jun. 14, 2023
Par Amount	[13]			$ 13,779
Cost	[13]			4
Fair Value				$ 4
[1] Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor. Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company. Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (“PRIME” or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment, the Company has provided the current interest rate in effect as of September 30, 2024. Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the SOFR or PRIME rate. These instruments are often subject to a SOFR or PRIME rate floor. Indicates an investment that is wholly or partially held by the Company through its wholly-owned financing subsidiary SLR HC BDC SPV LLC. Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company. Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the 1940 Act. If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2023, on a fair value basis, non-qualifying assets in our portfolio represented 20.8 % of the total assets of the Company. Floating rate debt investments typically bear interest at a rate determined by reference to either the Secured Overnight Financing Rate or the prime index rate , and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2023 Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of September 30, 2024, on a fair value basis, non-qualifying assets in our portfolio represented 12.7 % of the total assets of the Company. Certain tranches have a spread of S+ 795 and certain tranches have a spread of S+ 425 . BridgeBio Pharma, Inc. may elect to defer up to 3.00 % of the coupon as PIK Vapotherm, Inc. may elect to defer up to 9.00 % of the coupon as PIK. Denotes a Level 1 investment. Non-income producing security. Denotes a Level 1 investment. Non-income producing security. Aggregate net unrealized appreciation for U.S. federal income tax purposes is $ 287 ; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $ 1,208 and $ 921 , respectively, based on a tax cost of $ 72,335 . The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $ 241 ; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $ 600 and $ 841 , respectively, based on a tax cost of $ 63,516 . The Company generally acquires its investments in private transactions exempt from registration under the Securities Act. These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Parenthetical) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2024		Dec. 31, 2023
Schedule of Investments [Line Items]
Percentage of Non Qualifying Assets in the Portfolio of Total Assets	12.70%		20.80%
Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net	$ 287		$ (241)
Tax Basis of Investments, Gross, Unrealized Appreciation	1,208		600
Tax Basis of Investments, Gross, Unrealized Depreciation	921		841
Tax Basis of Investments, Cost for Income Tax Purposes	$ 72,335		$ 63,516
Percentage Representing Bank Debt Or Senior Secured Loans Owned	268%		275.40%
Percentage representing preferred equity in investments owned	9.80%
Percentage Representing Shares/Warrants Owned	0.30%		0.10%
Percentage Representing Total Investments In Investments Owned	278.10%	[1]	275.50%	[2]
Percentage Representing Cash Equivalents In Investments Owned			43.20%
Percentage Representing Marketable Securities In Investments Owned			5.33%
Percentage Representing Total Investments And Cash Equivalents In Investments Owned			318.70%
Percentage Representing Liabilities In Excess Of Other Assets In Investments Owned	(178.10%)		(218.70%)
Investment Owned, Net Assets, Percentage	100%		100%
Tranche S+795 [Member]
Schedule of Investments [Line Items]
Investment, Basis Spread, Variable Rate	795%
Tranche S+425 [Member]
Schedule of Investments [Line Items]
Investment, Basis Spread, Variable Rate	425%
BridgeBio Pharma Inc [Member]
Schedule of Investments [Line Items]
Rate of coupon as PIK			3%
Vapotherm, Inc. [Member]
Schedule of Investments [Line Items]
Rate of coupon as PIK			9%
[1] Aggregate net unrealized appreciation for U.S. federal income tax purposes is $ 287 ; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $ 1,208 and $ 921 , respectively, based on a tax cost of $ 72,335 . The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $ 241 ; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $ 600 and $ 841 , respectively, based on a tax cost of $ 63,516 . The Company generally acquires its investments in private transactions exempt from registration under the Securities Act. These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,047	$ 410	$ 2,396	$ 1,139

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b51 Arrangement Modified	false
Non rule 10b51 arrangement modified	false

N-2

N-2 - $ / shares		9 Months Ended
		Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cover [Abstract]
Entity Central Index Key		0001832148
Amendment Flag		false
Securities Act File Number		814-01382
Document Type		10-Q
Entity Registrant Name		SLR HC BDC LLC
Entity Address, Address Line One		500 Park Avenue
Entity Address, City or Town		New York
Entity Address, State or Province		NY
Entity Address, Postal Zip Code		10022
City Area Code		212
Local Phone Number		993-1670
Entity Emerging Growth Company		true
Entity Ex Transition Period		false
General Description of Registrant [Abstract]
Investment Objectives and Practices [Text Block]		Portfolio and Investment Activity During the three months ended September 30, 2024, we invested $8.0 million across 8 portfolio companies. This compares to investing $3.1 million in 7 portfolio companies during the three months ended September 30, 2023. Investments sold or prepaid during the three months ended September 30, 2024 totaled $3.5 million versus $1.4 million for the three months ended September 30, 2023. At September 30, 2024, our portfolio consisted of 31 portfolio companies and was invested 96.4% directly in senior secured loans, 3.5% in preferred equity and 0.1% in common equity/warrants, versus 26 portfolio companies invested more than 99.9% directly in senior secured loans and less than 0.1% in warrants at September 30, 2023, in each case measured at fair value. At September 30, 2024, 96.5% of our income producing investment portfolio was floating rate and 3.5% was fixed rate, measured at fair value. At September 30, 2023, 93.0% of our income producing investment portfolio was floating rate and 7.0% was fixed rate, measured at fair value.
Risk Factors [Table Text Block]		Item 1A. Risk Fac tors In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” in the February 27, 2024 filing of our Annual Report on Form 10-K, which could materially affect our business, financial condition and/or operating results. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. Other than the risk factor below, there have been no material changes during the nine months ended September 30, 2024 to the risk factors discussed in “Risk Factors” in the February 27, 2024 filing of our Annual Report on Form 10-K. General Economic and Market Risk . The value of the Company’s investments could be affected by factors affecting the economy and securities markets generally, such as real or perceived adverse economic conditions, supply and demand for particular instruments, changes in the general outlook for certain markets or corporate earnings, interest rates, announcements of political information or adverse investor sentiment generally. The market values of the Company’s investments may decline for a number of reasons, including increases in defaults resulting from changes in overall economic conditions and widening of credit spreads. Unfavorable market conditions may also increase funding costs, limit access to the capital markets or result in credit terms changing or credit becoming unavailable. These events could have an adverse effect on the Company’s investments and the Company’s overall performance. Various social and political circumstances in the U.S. and around the world (including wars and other forms of conflict, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may also contribute to increased market volatility and economic uncertainties or deterioration in the U.S. and worldwide. Such events, including rising trade tensions between the United States and China, other uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies with other countries, the large-scale invasion of Ukraine by Russia that began in February 2022 and resulting sanctions or other restrictive actions that the United States and other countries have imposed against Russia, the COVID-19 pandemic, certain regional bank failures, an inflationary environment and the ongoing war in the Middle East, could adversely affect the Company’s business, financial condition or results of operations. These market and economic disruptions could negatively impact the operating results of the Company’s Portfolio Investments. Additionally, the Federal Reserve raised the federal funds rate in 2022 and 2023. While the Federal Reserve cut its benchmark rate in the third quarter of 2024 for the first time since March 2020 and indicated that there may be additional rate cuts in 2024, future reductions to benchmark rates are not certain. Additionally, there can be no assurance that the Federal Reserve will not return to making upwards adjustments to the federal funds rate in the future. These developments, along with the United States government’s credit and deficit concerns, global economic uncertainties and market volatility and the impacts of COVID-19, could cause interest rates to be volatile, which may negatively impact the Company’s ability to access the debt markets and capital markets on favorable terms. Continuing market uncertainty may have a significant impact on the business of the Company. Among other things, the level of investment opportunities may decline from the Adviser’s current expectations. One possible consequence is that the Company may take a longer than anticipated period to invest capital and/or the Company may be relatively concentrated in a limited number of investments. Consequently, during this period, the returns (if any) realized by Unitholders may be substantially adversely affected by the unfavorable performance of a small number of these investments. Furthermore, market conditions may unfavorably impact the Company’s ability to secure leverage on terms as favorable as more established borrowers in the market, or to obtain any leverage on commercially favorable terms. To the extent the Company is able to secure financing for investments, increases in interest rates or in the risk spread demanded by financing sources would make the use of leverage more expensive and could limit the Company’s ability to structure and consummate its investments. Although the Adviser believes that recent market dislocations will result in attractive investment opportunities, the Company may not be able to time the acquisition or disposition of its investments correctly, which could result in further depreciation in values.
NAV Per Share	[1]	$ 22.03	$ 21.47	$ 21.56	$ 21.77
[1] Calculated using the average units outstanding method. Weighted average units outstanding for the nine months ended September 30, 2024 and September 30, 2023 were 1,113,111 and 1,015,916 , respectively.

Organization

Organization	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1. Organization SLR HC BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on July 7, 2020 as an externally managed, non-diversified closed-end management investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a BDC and a RIC, the Company is required to comply with certain regulatory requirements. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below. SLR Capital Partners, LLC (the “Adviser” or “SLR”) serves as the Company’s investment adviser pursuant to an investment management agreement with the Company (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). In connection with the Company’s formation, the Company issued and sold 40 units to the Adviser (the “Initial Unitholder”), which were acquired for an initial capital contribution of $ 1 on January 5, 2021 in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Company’s capital commitments total $ 83,850 . The Company’s initial drawdown occurred on March 8, 2021 with the sale and issuance of units at an aggregate purchase price of $ 3,500 or $ 29.30 per unit. Prior to the issuance of units on March 8, 2021, the Initial Unitholder’s initial seed capital was withdrawn from the Company and its units were canceled. As of September 30, 2024, $ 26,500 of capital commitments were drawn and $ 57,350 were unfunded. The Company pursues a corporate lending strategy focused on direct sourcing, underwriting and managing a diverse portfolio of private loans to U.S. healthcare companies. The Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”. The Company’s principal focus is to invest in two differentiated strategies: first lien healthcare cash flow loans and first lien life science loans. First lien healthcare cash flow loans are expected to be made to private equity-owned upper-middle-market healthcare companies with EBITDA (defined below) between approximately $ 25,000 and $ 100,000 . These aggregate loan tranches are expected to range in size from $ 100,000 to $ 300,000 . Healthcare cash flow loans are generally expected to have a five- to- six-year final maturity and are often repaid within three years . First lien life science loans are expected to be made to venture-capital owned pre-commercialization or early revenue drug and device development companies. These aggregate loan tranches are expected to range in size from $ 25,000 to $ 150,000 . Loans to life science companies are generally expected to have an initial interest-only period and then straight-line amortization with a four- to- five-year final maturity. These loans are often repaid within two to three years . The Company expects to primarily invest in non-investment grade debt instruments. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. The Company is organized for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). The Company was permitted to hold closings at any time during the offering period, which ended on December 31, 2022. The term of the Company is expected to be seven years from the Company’s final closing with the Access Fund, which was held on February 11, 2021, unless the Company is terminated earlier or causes its units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange (an “Exchange Listing”) as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one-year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a non-1940 Act vote as described in Item 11 of the Company’s Form 10. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31. At any time prior to the end of the term, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause its units (or securities into which the units are converted or exchanged) to be listed for trading on a national securities exchange. In connection with any such Exchange Listing, subject to the requirements of the 1940 Act and applicable law, the board of directors may, without the approval of Unitholders, cause the Company to complete (i) an initial public offering, (ii) a merger with another entity, including an affiliated company, subject to any limitations under the 1940 Act, (iii) the sale, exchange or disposition of all or a portion of the assets of the Company, or (iv) a conversion of the Company into a corporation incorporated in a state determined by the board of directors, either through a conversion in accordance with applicable law, a merger with or into an existing corporation or otherwise in which all units will be converted into or exchanged for shares of common stock of the resulting corporation. If the Company is unable to effectuate an Exchange Listing prior to the end of the term, the Company will use commercially reasonable efforts to wind down or liquidate pursuant to the procedures set forth in the LLC Agreement.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X, as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2024. In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of consolidated financial statements, have been included. The significant accounting policies consistently followed by the Company are: (a) Investment transactions are accounted for on the trade date; (b) In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows: (i) securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation; (ii) exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes; (iii) short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and (iv) securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below: a. the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment; b. preliminary valuation conclusions are then documented and discussed with senior management of the Adviser; c. the audit committee of the board of directors (the “Board”) reviews the preliminary valuations of the Adviser and third-party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and d. the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third-party valuation specialist, if any, which may from time to time be engaged by the Board. The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion. The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 under the 1940 Act; and (6) maintain recordkeeping requirements under Rule 2a-5. When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the nine months ended September 30, 2024, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process. ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy: Level 1 : Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date. Level 2 : Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices. Level 3 : Unobservable inputs for the asset or liability. In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience. (c) Gains or losses on investments are calculated by using the specific identification method. (d) The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other non-recurring fee income as well as management fees and other fee income for services rendered, if any, are recorded as other income when earned. (e) The Company intends to comply with the applicable provisions of the Code pertaining to RICs to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4 % excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate. (f) Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP. (g) Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually. (h) In accordance with Regulation S-X and ASC Topic 810— Consolidation , the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company. (i) The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company. (j) In accordance with ASC 835-30, the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method. (k) The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC 946-20-25. (l) Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such non-accrual investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment. (m) The Company records expenses directly related to its organization as incurred. (n) The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents. Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.

Agreements and Related Party Tr

Agreements and Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Agreements And Related Party Transactions [Abstract]
Agreements and Related Party Transactions	Note 3. Agreements and Related Party Transactions Pursuant to the Investment Management Agreement we have entered into with the Adviser, we intend to pay the Adviser certain management and incentive fees prior to and following an Exchange Listing. Prior to an Exchange Listing, the Adviser has been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay an administration fee to the Administrative Coordinator for such administrative and coordination services. Following an Exchange Listing, we intend to enter into a separate administration agreement with an affiliate pursuant to which administrative services would be provided to the Company, as described further below. The cost of the base management fee, the incentive fee and the administration fee will ultimately be borne by our Unitholders. Management Fees The Company will pay the Adviser a management fee prior to an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Pre-Exchange Listing Management Fee”) and a management fee following an Exchange Listing (as the same may be adjusted pursuant to the LLC Agreement and the Investment Management Agreement, the “Post-Exchange Listing Management Fee” and, together with the Pre-Exchange Listing Management Fee, the “Management Fee”). The Management Fee will be payable quarterly in arrears, as follows: • Pre-Exchange Listing . Prior to an Exchange Listing, the Pre-Exchange Listing Management Fee will be calculated as of the close of business on the last day of each calendar quarter in an amount equal to 1.50 % per annum of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company used to make Portfolio Investments and (ii) the total amount of credit drawn on subscription or similarly structured credit facilities). • Post-Exchange Listing . Following an Exchange Listing, the Post-Exchange Listing Management Fee will be an amount equal to 1.50 % per annum of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters; provided, however, the Post-Exchange Listing Management Fee will be calculated at an annual rate of 1.00 % of the average value of the Company’s total assets at the end of the two most recently completed calendar quarters that exceeds the product of (i) 200 % and (ii) the value of the Company’s total net assets at the end of the immediately preceding calendar quarter. The Management Fee will be appropriately adjusted for any stub period. The Adviser may arrange for the Company to direct to a placement agent any portion of the Management Fee which the Adviser is owed for purposes of paying any placement fee that the Adviser owes to such placement agent. The Adviser will have the right, in its sole discretion, to waive or reduce, as well as recoup in a subsequent period, the Management Fee to which the Adviser is entitled in respect of all Unitholders’ units in any particular calendar quarter. Any such Management Fee may be recouped by the Adviser in a future calendar quarter within three years of the date of the applicable waiver of the Management Fee. No Management Fees have been waived as of September 30, 2024. Incentive Fee Distributions . Prior to an Exchange Listing, the Company makes distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, prepayment fees and exit fees, other than Disposition Proceeds, less Company expenses. The Adviser apportions each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. Pre-Exchange Listing Incentive Fee . Prior to an Exchange Listing, and subject to availability, the Company will cause distributable cash to be distributed to Unitholders and to be paid to the Adviser as an incentive fee (the “Pre-Exchange Listing Incentive Fee”). Amounts of Investment Proceeds apportioned to Unitholders are divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority: (i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a Pre-Exchange Listing Incentive Fee, on the other hand, in the following amounts and order of priority: (A) First, Return of Capital Contributions: 100 % to such Unitholder until such Unitholder has received cumulative distributions of Investment Proceeds pursuant to this clause (A) equal to such Unitholder’s total capital contributions to the Company (including amounts contributed to pay Pre-Exchange Listing Management Fees, Pre-Exchange Listing Administration Fees (defined below), Organizational Expenses (defined below) and other Company expenses); (B) Second, Unitholder Preferred Return: 100 % of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and clauses (ii)(A) and (ii)(C) below equal to 6 % per annum, compounded annually, on Unitholders’ capital contributions to the Company (including amounts contributed to pay Pre-Exchange Listing Management Fees, Pre-Exchange Listing Administration Fees, Organizational Expenses and other Company expenses), determined on the basis of all capital contributions made by such Unitholder and considering all distributions (including the subject distribution) under this “—Pre-Exchange Listing Incentive Fee” made to such Unitholder (computed from the dates that such capital contributions were due (or, if actually made later, the date on which such capital contributions were actually made) until the date that the Company, in its sole discretion, designates distributable cash as available for distribution or, if no such designation is made, the occurrence of an Event of Dissolution, as defined in the LLC Agreement) (the “Preferred Return”); (C) Third, Adviser Catch Up: 100 % of all remaining Disposition Proceeds to the Adviser as a Pre-Exchange Listing Incentive Fee, until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) below equal to 10 % of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (B) above and this clause (C) and clauses (ii)(A) and (ii)(B) below; and (D) Fourth, 90 %/ 10 %: 90 % of all remaining Disposition Proceeds to Unitholders and 10 % of all remaining Disposition Proceeds to the Adviser as a Pre-Exchange Listing Incentive Fee. In no event will the Adviser receive amounts of Pre-Exchange Listing Incentive Fees under clauses (i)(C) and (i)(D) above in excess of the percentage of the Disposition Proceeds actually distributed to Unitholders pursuant to clauses (i)(B), (i)(C) and (i)(D) above. In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceed 20 % of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation. (ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as a Pre-Exchange Listing Incentive Fee, on the other hand, in the following amounts and order of priority: (A) First, Unitholder Preferred Return: 100 % of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) above equal to the Preferred Return; (B) Second, Adviser Catch Up: 100 % of all remaining Current Proceeds to the Adviser as a Pre-Exchange Listing Incentive Fee until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) above equal to 10 % of the total amounts due to Unitholders and earned by the Adviser pursuant to clause (A) above and this clause (B) and pursuant to clause (i)(B) and clause (i)(C) above; and (C) Third, 90 %/ 10 %: 90 % of all remaining Current Proceeds to Unitholders and 10 % of all remaining Current Proceeds to the Adviser as a Pre-Exchange Listing Incentive Fee. In no event will the Adviser receive amounts of Pre-Exchange Listing Incentive Fees under clauses (ii)(B) and (ii)(C) above in excess of the percentage of the Current Proceeds actually distributed to Unitholders pursuant to clauses (ii)(A), (ii)(B) and (ii)(C) above. Post-Exchange Listing Incentive Fee . Following an Exchange Listing, the Company will pay an incentive fee to the Adviser consisting of two parts, as follows (the “Post-Exchange Listing Incentive Fee” and, together with the Pre-Exchange Listing Incentive Fee, the “Incentive Fee”): (i) Pre-Incentive Fee Net Investment Income. One part will be calculated and payable quarterly in arrears based on the net investment income for the immediately preceding calendar quarter. a. For this purpose, Pre-Incentive Fee Net Investment Income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies) accrued by the Company during the calendar quarter, minus the Company’s operating expenses for the quarter (including the Post-Exchange Listing Management Fee, expenses payable under an administration agreement, and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the Post-Exchange Listing Incentive Fee). b. Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Pre-Incentive Fee Net Investment Income, expressed as a rate of return on the value of the Company’s net assets at the end of the immediately preceding calendar quarter, will be compared to a “hurdle rate” of 1.50 % per quarter ( 6.00 % annualized). The Company’s Pre-Incentive Fee Net Investment Income used to calculate this part of the Post-Exchange Listing Incentive Fee is also included in the amount of its gross assets used to calculate the 1.50 % Post-Exchange Listing Management Fee. c. The Company will pay the Adviser a Post-Exchange Listing Incentive Fee with respect to the Company’s Pre-Incentive Fee Net Investment Income in each calendar quarter as follows: i. no Post-Exchange Listing Incentive Fee in any calendar quarter in which the Company’s Pre-Incentive Fee Net Investment Income does not exceed the quarterly hurdle rate of 1.50%; ii. 100 % of the Company’s Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 1.875 % in any calendar quarter ( 7.5 % annualized); this portion of the Pre-Incentive Fee Net Investment Income (which exceeds the hurdle but is less than 1.875%) is referred to herein as the “catch-up.” The “catch-up” is meant to provide the Adviser with 20 % of the Company’s Pre-Incentive Fee Net Investment Income as if a hurdle did not apply if this Pre-Incentive Fee Net Investment Income exceeds 1.875 % in any calendar quarter; and iii. 20% of the amount of the Company’s Pre-Incentive Fee Net Investment Income, if any, that exceeds 1.875% in any calendar quarter (7.5% annualized) payable to the Adviser (once the hurdle is reached and the catch-up is achieved, 20 % of all Pre-Incentive Fee Net Investment Income thereafter is allocated to the Adviser). These calculations will be appropriately pro-rated for any period of less than three months. (ii) Capital Gains Fee. The second part of the Post-Exchange Listing Incentive Fee, the “Capital Gains Fee”, will be determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement as set forth below), commencing as of the end of the first fiscal year following an Exchange Listing, and will equal 20.0 % of the Company’s realized capital gains, if any, on a cumulative basis through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation as of each fiscal year end, less the amount of any previously paid capital gain Post-Exchange Listing Incentive Fees, with respect to the Company; provided that the Post-Exchange Listing Incentive Fee determined as of the end of the fiscal year in which an Exchange Listing is completed will be calculated for a period of shorter than twelve calendar months to take into account any realized capital gains computed net of all realized capital losses and unrealized capital depreciation. In the event that the Investment Management Agreement will terminate as of a date that is not a calendar year end, the termination date will be treated as though it were a calendar year end for purposes of calculating and paying a Capital Gains Fee. Administration Fees and Expenses Pre-Exchange Listing Administration Fees . The Company will pay SLR, in its capacity as the Administrative Coordinator, a fee (the “Pre-Exchange Listing Administration Fee” or “Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08 % per annum of the average Cost Basis (defined as, as of any date, the aggregate accreted and amortized cost of all Portfolio Investments, including (i) any amounts reinvested in Portfolio Investments and (ii) the cost of Portfolio Investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The Pre-Exchange Listing Administration Fee will not offset any fees paid to the Adviser. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain on-going, routine, non-investment-related administrative services for the Company, (ii) the coordination of various third-party services needed or required by the Company and (iii) certain Unitholder servicing functions. The Pre-Exchange Listing Administration Fee will be appropriately adjusted for any stub period. The Administrative Coordinator will have the right, in its sole discretion, to waive, as well as recoup in a subsequent period, the Pre-Exchange Listing Administration Fee to which it is entitled in respect of all Unitholders’ units in any particular calendar quarter. Any such Pre-Exchange Listing Administration Fee may be recouped by the Administrative Coordinator in a future calendar quarter within three years of the date of the applicable waiver of the Pre-Exchange Listing Administration Fee. No administration fees have been waived as of September 30, 2024. Post-Exchange Listing Administration Expenses . In connection with an Exchange Listing, and subject to Board approval, the Company intends to enter into an administration agreement with SLR Capital Management, LLC (“SCM”) pursuant to which SCM will provide administrative services to the Company. For providing these services, facilities and personnel, the Company will reimburse SCM for the Company’s allocable portion of overhead and other expenses incurred by SCM in performing its obligations under the administration agreement (together with the Pre-Exchange Listing Administration Fee, the “Administration Expenses”). For the three and nine months ended September 30, 2024, the Company incurred $ 186 and $ 507 , respectively, in Management Fees, $ 14 and $ 39 , respectively, in Administration Fees and $ 447 and $ 447 , respectively, in Incentive Fees. For the three and nine months ended September 30, 2023, the Company incurred $ 143 and $ 408 , respectively, in Management Fees, $ 10 and $ 30 , respectively, in Administration Fees and $ 0 and $ 0 , respectively, in Incentive Fees. In addition, prior to an Exchange Listing, the aggregate amount of certain annual operating expenses relating to Unitholders investing directly in the Company will not exceed the following limits in any fiscal year: (A) if the Company has less than or equal to $ 400,000 in commitments, an amount equal to the sum of (x) the product of the commitments and 0.0025 and (y) $ 1,250 , or (B) if the Company has greater than $ 400,000 in commitments, $ 2,250 (such figure, the “Operating Expense Cap”). Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, (i) the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder, (ii) the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the Company’s Portfolio Investments at each quarter end and (iii) the Operating Expense Cap will no longer apply upon the effectuation of an Exchange Listing. The Adviser or Administrative Coordinator and/or their affiliates have advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of units and the formation and establishment of the Company (the “Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) will be reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $ 500 . The Company will be responsible for and pay (or reimburse) the Organizational Expenses subject to the cap described in the preceding sentence. Accordingly, in 2021, $ 177 of offering expenses were charged to capital and $ 229 of organizational costs were expensed.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 4. Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows: Level 1. Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access. Level 2. Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following: a) Quoted prices for similar assets or liabilities in active markets; b) Quoted prices for identical or similar assets or liabilities in non-active markets; c) Pricing models whose inputs are observable for substantially the full term of the asset or liability; and d) Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability. Level 3. Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability. When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). Gains and losses for assets and liabilities categorized within the Level 3 tables below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3). A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1. The following tables present the balances of assets measured at fair value on a recurring basis, as of September 30, 2024 and December 31, 2023: Fair Value Measurements As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ — $ — $ 69,998 $ 69,998 Preferred Equity — — 2,563 2,563 Common Equity/Warrants 1 — 60 61 Total Investments $ 1 $ — $ 72,621 $ 72,622 While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at September 30, 2024, the fair value of the SPV Facility and the Subscription Facility would be $ 25,980 and $ 22,700 , respectively. All debt obligations would be considered Level 3 liabilities and would be valued with market yield as the unobservable input. Fair Value Measurements As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ — $ — $ 63,268 $ 63,268 Common Equity/Warrants 1 — 6 7 Total Investments $ 1 $ — $ 63,274 $ 63,275 While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2023, the fair value of the SPV Facility and the Subscription Facility would be $ 24,210 and $ 17,550 , respectively. All debt obligations would be considered Level 3 liabilities and would be valued with market yield as the unobservable input. The following tables provide a summary of the changes in fair value of Level 3 assets for the three and nine months ended September 30, 2024, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at September 30, 2024: Bank Debt/Senior Preferred Equity Common Equity/ Warrants Total Fair value, June 30, 2024 $ 67,254 $ — $ 13 $ 67,267 Total gains or losses included in earnings: Net realized gain — — 6 6 Net change in unrealized gain (loss) 417 130 51 598 Purchase of investment securities* 7,015 2,433 30 9,478 Proceeds from dispositions of investment securities ( 4,688 ) — ( 40 ) ( 4,728 ) Transfers into Level 3 — — — — Transfers out of Level 3 — — — — Fair value, September 30, 2024 $ 69,998 $ 2,563 $ 60 $ 72,621 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 423 $ 130 $ 51 $ 604 * Includes PIK capitalization and accretion of discount Bank Debt/Senior Preferred Equity Common Equity/ Warrants Total Fair value, December 31, 2023 $ 63,268 $ — $ 6 $ 63,274 Total gains or losses included in earnings: Net realized gain — — 6 6 Net change in unrealized gain (loss) 343 130 56 529 Purchase of investment securities* 16,301 2,433 32 18,766 Proceeds from dispositions of investment securities ( 9,914 ) — ( 40 ) ( 9,954 ) Transfers into Level 3 — — — — Transfers out of Level 3 — — — — Fair value, September 30, 2024 $ 69,998 $ 2,563 $ 60 $ 72,621 Unrealized gains (losses) for the period relating to those Net change in unrealized gain (loss) $ 387 $ 130 $ 56 $ 573 * Includes PIK capitalization and accretion of discount The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2023: Bank Debt/Senior Warrants Total Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 254 ( 15 ) 239 Purchase of investment securities* 26,306 15 26,321 Proceeds from dispositions of investment securities ( 7,178 ) ( 5 ) ( 7,183 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, December 31, 2023 $ 63,268 $ 6 $ 63,274 Unrealized gains (losses) for the period relating to those Net change in unrealized gain (loss) $ 259 $ ( 18 ) $ 241 * Includes PIK capitalization and accretion of discount Quantitative Information about Level 3 Fair Value Measurements The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company. Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities. Quantitative information about the Company’s Level 3 asset fair value measurements as of September 30, 2024 is summarized in the table below: Asset or Fair Value at Principal Valuation Unobservable Input Range (Weighted Bank Debt / Senior Secured Loans Asset $ 69,998 Income Approach Market Yield 9.7 % – 16.0 % ( 11.7 %) Preferred Equity Asset $ 2,563 Income Approach Market Yield 9.0 % – 9.0 % ( 9.0 %) Common Equity Asset $ 58 Transaction Price* N/A N/A Warrants Asset $ 2 Market Approach Volatility 18.3 % - 18.3 % ( 18.3 %) * This asset was valued at $ 2.18 per share, which is the price per share paid to the stockholders at the time of the closing of the transaction. Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below: Asset or Fair Value at Principal Valuation Unobservable Input Range (Weighted Bank Debt / Senior Secured Loans Asset $ 63,268 Income Approach Market Yield 10.6 % –  17.6 % ( 13.0 %) Warrants Asset $ 6 Market Approach Volatility 18.9 % -  18.9 % ( 18.9 %) Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving bid-ask spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. Weighted averages in the above tables are calculated based on fair value of the underlying assets.

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Note 5. Debt SPV Facility —On February 18, 2022, the Company, through its wholly-owned subsidiary, SLR HC BDC SPV LLC, entered into the $ 50,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. On May 30, 2023, the SPV Facility was amended, increasing commitments to $ 75,000 . On January 23, 2024, the SPV Facility commitments were reduced to $ 35,000 . The stated interest rate on the SPV Facility is Term SOFR plus 3.07 % with no SOFR floor requirement, and the final maturity date is February 18, 2027 . The fee on undrawn commitments is currently 0.875 %. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV Facility also includes usual and customary events of default for credit facilities of this nature. As of September 30, 2024, there were $ 25,980 of borrowings outstanding under the SPV Facility. Subscription Facility —On March 19, 2021, the Company established the $ 25,000 Subscription Facility with ING Capital LLC. The stated interest rate on the Subscription Facility is SOFR plus 2.75 - 3.00 %. On December 14, 2021, the Subscription Facility was amended, allowing for increased borrowing base availability, among other changes. On June 14, 2023, a second amendment to the Subscription Facility was entered into, which replaced the benchmark rate of LIBOR with SOFR. On March 6, 2024, a third amendment to the Subscription Facility was entered into, extending the maturity date to March 14, 2025 , among other minor changes. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of September 30, 2024, there were $ 22,700 of borrowings outstanding under the Subscription Facility. The average annualized interest cost for borrowings for the nine months ended September 30, 2024 and the year ended December 31, 2023 was 8.50 % and 8.11 %, respectively. These costs are exclusive of other credit facility expenses such as unused fees. The maximum amount borrowed on the credit facilities during the nine months ended September 30, 2024 and the year ended December 31, 2023 was $ 49,430 and $ 44,010 , respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of September 30, 2024 and December 31, 2023 was $ 8,128 and $ 11,545 , respectively, comprised of the following: September 30, 2024 December 31, 2023 AAH Topco, LLC $ 1,301 $ 2,262 OIS Management Services, LLC 1,166 1,710 CVAUSA Management, LLC 1,059 1,059 Arcutis Biotherapeutics, Inc. 837 — Western Veterinary Partners LLC 674 — Eyesouth Eye Care Holdco LLC 649 343 SPR Therapeutics, Inc. 626 — FE Advance, LLC 451 — Southern Orthodontic Partners Management, LLC 391 1,347 United Digestive MSO Parent, LLC 365 391 Medrina, LLC 239 239 Urology Management Holdings, Inc. 172 151 Exactcare Parent, Inc. 102 102 WCI-BXC Purchaser, LLC 96 96 Ardelyx, Inc. — 1,345 Retina Midco, Inc. — 966 Orthopedic Care Partners Management, LLC — 901 Vertos Medical, Inc. — 283 UVP Management, LLC — 218 SunMed Group Holdings, LLC — 132 Total Commitments $ 8,128 $ 11,545 The credit agreements governing the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of September 30, 2024 and December 31, 2023, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment. In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with off-balance sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of off-balance sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities. As of September 30, 2024, we held no such contracts. From time to time, the Company may become a party to certain legal proceedings incidental to the normal course of its business. As of September 30, 2024 and December 31, 2023, management is not aware of any material pending or threatened litigation that would require accounting recognition or financial statement disclosure.

Unitholders' Capital

Unitholders' Capital	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Unitholders' Capital	Note 7. Unitholders’ Capital Transactions in Unitholders’ capital were as follows: Three months ended Three months ended Units at beginning of period 1,185,276 1,069,642 Units issued — — Units issued and outstanding at end of period 1,185,276 1,069,642 Nine months ended Nine months ended Units at beginning of period 1,069,642 888,565 Units issued 115,634 181,077 Units issued and outstanding at end of period 1,185,276 1,069,642

Financial Highlights

Financial Highlights	9 Months Ended
	Sep. 30, 2024
Investment Company, Financial Highlights [Abstract]
Financial Highlights	Note 8. Financial Highlights The following is a schedule of financial highlights for the nine months ended September 30, 2024 and September 30, 2023: Nine months ended Nine months ended Per Share Data: (a) Net asset value per unit, beginning of period $ 21.47 $ 21.77 Net investment income 1.68 0.95 Net realized and unrealized gain (loss)* 0.45 0.24 Net increase in Unitholders’ capital resulting from operations 2.13 1.19 Distributions to Unitholders: From distributable earnings ( 1.57 ) ( 1.40 ) Net asset value per unit, end of period $ 22.03 $ 21.56 Total Return (b)(c) 9.92 % 5.47 % Unitholders’ capital, end of period $ 26,117 $ 23,065 Units outstanding, end of period 1,185,276 1,069,642 Ratios to average net assets of Unitholders’ Capital (c): Net investment income 7.74 % 4.35 % Operating expenses 6.04 % 4.50 % Interest and other credit facility expenses 13.40 % 12.83 % Total expenses 19.44 % 17.33 % Average debt outstanding $ 43,867 $ 30,079 Portfolio turnover ratio 13.3 % 11.1 % (a) Calculated using the average units outstanding method. Weighted average units outstanding for the nine months ended September 30, 2024 and September 30, 2023 were 1,113,111 and 1,015,916 , respectively. (b) Calculated as the change in net asset value (“NAV”) per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. (c) Not annualized for periods less than one year. * Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 9. Subsequent Events The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure in these consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on a Recurring Basis	The following tables present the balances of assets measured at fair value on a recurring basis, as of September 30, 2024 and December 31, 2023: Fair Value Measurements As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ — $ — $ 69,998 $ 69,998 Preferred Equity — — 2,563 2,563 Common Equity/Warrants 1 — 60 61 Total Investments $ 1 $ — $ 72,621 $ 72,622 Fair Value Measurements As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Bank Debt/Senior Secured Loans $ — $ — $ 63,268 $ 63,268 Common Equity/Warrants 1 — 6 7 Total Investments $ 1 $ — $ 63,274 $ 63,275
Summary of Changes in Fair Value of Level 3 Assets	The following tables provide a summary of the changes in fair value of Level 3 assets for the three and nine months ended September 30, 2024, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at September 30, 2024: Bank Debt/Senior Preferred Equity Common Equity/ Warrants Total Fair value, June 30, 2024 $ 67,254 $ — $ 13 $ 67,267 Total gains or losses included in earnings: Net realized gain — — 6 6 Net change in unrealized gain (loss) 417 130 51 598 Purchase of investment securities* 7,015 2,433 30 9,478 Proceeds from dispositions of investment securities ( 4,688 ) — ( 40 ) ( 4,728 ) Transfers into Level 3 — — — — Transfers out of Level 3 — — — — Fair value, September 30, 2024 $ 69,998 $ 2,563 $ 60 $ 72,621 Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period: Net change in unrealized gain (loss) $ 423 $ 130 $ 51 $ 604 * Includes PIK capitalization and accretion of discount Bank Debt/Senior Preferred Equity Common Equity/ Warrants Total Fair value, December 31, 2023 $ 63,268 $ — $ 6 $ 63,274 Total gains or losses included in earnings: Net realized gain — — 6 6 Net change in unrealized gain (loss) 343 130 56 529 Purchase of investment securities* 16,301 2,433 32 18,766 Proceeds from dispositions of investment securities ( 9,914 ) — ( 40 ) ( 9,954 ) Transfers into Level 3 — — — — Transfers out of Level 3 — — — — Fair value, September 30, 2024 $ 69,998 $ 2,563 $ 60 $ 72,621 Unrealized gains (losses) for the period relating to those Net change in unrealized gain (loss) $ 387 $ 130 $ 56 $ 573 * Includes PIK capitalization and accretion of discount Bank Debt/Senior Warrants Total Fair value, December 31, 2022 $ 43,886 $ 11 $ 43,897 Total gains or losses included in earnings: Net realized gain — — — Net change in unrealized gain (loss) 254 ( 15 ) 239 Purchase of investment securities* 26,306 15 26,321 Proceeds from dispositions of investment securities ( 7,178 ) ( 5 ) ( 7,183 ) Transfers into Level 3 — — — Transfers out of Level 3 — — — Fair value, December 31, 2023 $ 63,268 $ 6 $ 63,274 Unrealized gains (losses) for the period relating to those Net change in unrealized gain (loss) $ 259 $ ( 18 ) $ 241 * Includes PIK capitalization and accretion of discount
Summary of Company's Level 3	Quantitative information about the Company’s Level 3 asset fair value measurements as of September 30, 2024 is summarized in the table below: Asset or Fair Value at Principal Valuation Unobservable Input Range (Weighted Bank Debt / Senior Secured Loans Asset $ 69,998 Income Approach Market Yield 9.7 % – 16.0 % ( 11.7 %) Preferred Equity Asset $ 2,563 Income Approach Market Yield 9.0 % – 9.0 % ( 9.0 %) Common Equity Asset $ 58 Transaction Price* N/A N/A Warrants Asset $ 2 Market Approach Volatility 18.3 % - 18.3 % ( 18.3 %) * This asset was valued at $ 2.18 per share, which is the price per share paid to the stockholders at the time of the closing of the transaction. Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2023 is summarized in the table below: Asset or Fair Value at Principal Valuation Unobservable Input Range (Weighted Bank Debt / Senior Secured Loans Asset $ 63,268 Income Approach Market Yield 10.6 % –  17.6 % ( 13.0 %) Warrants Asset $ 6 Market Approach Volatility 18.9 % -  18.9 % ( 18.9 %)

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Summary of Unfunded Commitments	The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of September 30, 2024 and December 31, 2023 was $ 8,128 and $ 11,545 , respectively, comprised of the following: September 30, 2024 December 31, 2023 AAH Topco, LLC $ 1,301 $ 2,262 OIS Management Services, LLC 1,166 1,710 CVAUSA Management, LLC 1,059 1,059 Arcutis Biotherapeutics, Inc. 837 — Western Veterinary Partners LLC 674 — Eyesouth Eye Care Holdco LLC 649 343 SPR Therapeutics, Inc. 626 — FE Advance, LLC 451 — Southern Orthodontic Partners Management, LLC 391 1,347 United Digestive MSO Parent, LLC 365 391 Medrina, LLC 239 239 Urology Management Holdings, Inc. 172 151 Exactcare Parent, Inc. 102 102 WCI-BXC Purchaser, LLC 96 96 Ardelyx, Inc. — 1,345 Retina Midco, Inc. — 966 Orthopedic Care Partners Management, LLC — 901 Vertos Medical, Inc. — 283 UVP Management, LLC — 218 SunMed Group Holdings, LLC — 132 Total Commitments $ 8,128 $ 11,545

Unitholders' Capital (Tables)

Unitholders' Capital (Tables)	9 Months Ended
	Sep. 30, 2024
Limited Liability Company (LLC) Members' Equity [Abstract]
Summary of Limited Liability Company Unit Holders Capital	Transactions in Unitholders’ capital were as follows: Three months ended Three months ended Units at beginning of period 1,185,276 1,069,642 Units issued — — Units issued and outstanding at end of period 1,185,276 1,069,642 Nine months ended Nine months ended Units at beginning of period 1,069,642 888,565 Units issued 115,634 181,077 Units issued and outstanding at end of period 1,185,276 1,069,642

Financial Highlights (Tables)

Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2024
Investment Company, Financial Highlights [Abstract]
Summary of Financial Highlights	The following is a schedule of financial highlights for the nine months ended September 30, 2024 and September 30, 2023: Nine months ended Nine months ended Per Share Data: (a) Net asset value per unit, beginning of period $ 21.47 $ 21.77 Net investment income 1.68 0.95 Net realized and unrealized gain (loss)* 0.45 0.24 Net increase in Unitholders’ capital resulting from operations 2.13 1.19 Distributions to Unitholders: From distributable earnings ( 1.57 ) ( 1.40 ) Net asset value per unit, end of period $ 22.03 $ 21.56 Total Return (b)(c) 9.92 % 5.47 % Unitholders’ capital, end of period $ 26,117 $ 23,065 Units outstanding, end of period 1,185,276 1,069,642 Ratios to average net assets of Unitholders’ Capital (c): Net investment income 7.74 % 4.35 % Operating expenses 6.04 % 4.50 % Interest and other credit facility expenses 13.40 % 12.83 % Total expenses 19.44 % 17.33 % Average debt outstanding $ 43,867 $ 30,079 Portfolio turnover ratio 13.3 % 11.1 %

Organization - Additional Infor

Organization - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended
	Mar. 08, 2021	Jan. 05, 2021	Sep. 30, 2024
Initial Unitholder [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common shares shares		40
Share price	$ 29.3	$ 1
Capital commitments			$ 83,850
Issuance of common shares value	$ 3,500
Withdrawal of capital commitments			26,500
Unfunded commitments			$ 57,350
First Lien Health Care Cash Flow Loans [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument maturity date			five-to-six-year
Debt Instrument, Frequency of Periodic Payment			three years
Debt Instrument, Payment Terms			often repaid within three years
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 300,000
Debt Instrument, Term			6 years
First Lien Health Care Cash Flow Loans [Member] | Maximum [Member] | EBITDA Concentration Risk [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Earnings Before Interest Tax Depreciation And Amortization			$ 100,000
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 100,000
Debt Instrument, Term			5 years
First Lien Health Care Cash Flow Loans [Member] | Minimum [Member] | EBITDA Concentration Risk [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Earnings Before Interest Tax Depreciation And Amortization			$ 25,000
First Lien Life Science Loans [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument maturity date			four-to-five-year
Debt Instrument, Payment Terms			often repaid within two to three years
First Lien Life Science Loans [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 150,000
Debt Instrument, Term			5 years
Debt Instrument, Frequency of Periodic Payment			three years
First Lien Life Science Loans [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument carrying amount			$ 25,000
Debt Instrument, Term			4 years
Debt Instrument, Frequency of Periodic Payment			two years

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2024
Schedule Of Significant Accounting Policies [Line Items]
Excise tax rate	4%

Agreements and Related Party _2

Agreements and Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Agreements And Related Party Transactions [Line Items]
Percentage of pre exchange management fee on invested capital				1.50%
Percentage of Post-Exchange Listing Management Fee on Entity Average Assets				1.50%
Percentage of Entity Average Assets Threshold				1%
Precentage of product payment				200%
Percentage of cummulative capital realized gains				20%
Percentage of Post-Exchange Listing Management Fee on Entity Gross Assets				1.50%
Percentage pre incentive fee net investment income				100%
Percentage of realized capital gains				20%
Percentage of average cost basis				0.08%
Management fee expense		$ 186	$ 143	$ 507	$ 408
Administrative fees expense		14	10	39	30
Incentive fee expense		447	$ 0	$ 447	$ 0
Product of capital commitment				0.0025
Affiliate Costs				$ 500
Offering expenses	$ 177
Organizational costs	$ 229
Type of agreement, First [Member]
Agreements And Related Party Transactions [Line Items]
Precentage of return of capital contributions				100%
Percentage of current proceeds to unitholders				100%
Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				100%
Percentage of current proceeds to advisers				100%
Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to adviser				100%
Quarterly [Member]
Agreements And Related Party Transactions [Line Items]
Percentage pre incentive fee net investment income				1.875%
Percentage of hurdle rate				1.50%
Annually [Member]
Agreements And Related Party Transactions [Line Items]
Percentage pre incentive fee net investment income				7.50%
Percentage of hurdle rate				6%
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of current proceeds to unitholders				90%
Percentage of current proceeds to advisers				10%
Pre Exchange Listing Incentive Fee [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				90%
Percentage of remaining disposition proceeds to adviser				10%
Adviser [Member]
Agreements And Related Party Transactions [Line Items]
Percentage pre incentive fee net investment income				20%
Minimum [Member]
Agreements And Related Party Transactions [Line Items]
Commitments		400,000		$ 400,000
Capital commitments				$ 1,250
Minimum [Member] | Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				6%
Minimum [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Pecentage of amount due to unitholders				10%
Percentage of current proceeds to unitholders				10%
Minimum [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				10%
Maximum [Member]
Agreements And Related Party Transactions [Line Items]
Commitments		$ 400,000		$ 400,000
Capital commitments				$ 2,250
Maximum [Member] | Type of agreement, Second [Member]
Agreements And Related Party Transactions [Line Items]
Pecentage of amount due to unitholders				10%
Maximum [Member] | Type of agreement, Third [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of current proceeds to unitholders				90%
Maximum [Member] | Type of agreement, Fourth [Member]
Agreements And Related Party Transactions [Line Items]
Percentage of remaining disposition proceeds to unitholders				90%

Fair Value - Summary of Assets

Fair Value - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	$ 72,622	$ 63,275
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	1	1
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	72,621	63,274
Bank Debt/Senior Secured Loans [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	69,998	63,268
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	69,998	63,268
Preferred Equity [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	2,563
Preferred Equity [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0
Preferred Equity [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	2,563
Common Equity/Warrants [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	61	7
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	1	1
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	0	0
Common Equity/Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments, Fair Value Disclosure	$ 60	$ 6

Fair Value - Summary of Changes

Fair Value - Summary of Changes in Fair Value of Level 3 Assets (Detail) - Investments [Member] - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2024		Sep. 30, 2024		Dec. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		$ 67,267		$ 63,274		$ 43,897
Total gains or losses included in earnings:
Purchase of investment securities		9,478	[1]	18,766	[2]	26,321	[3]
Proceeds from dispositions of investment securities		(4,728)		(9,954)		(7,183)
Transfers into Level 3		0		0		0
Transfers out of Level 3		0		0		0
Closing balance		72,621		72,621		63,274
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)		604		573		241
Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Net realized gain		6		6		0
Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Net realized gain		598		529		239
Bank Debt/Senior Secured Loans [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		67,254		63,268		43,886
Total gains or losses included in earnings:
Purchase of investment securities		7,015	[1]	16,301	[2]	26,306	[3]
Proceeds from dispositions of investment securities		(4,688)		(9,914)		(7,178)
Transfers into Level 3		0		0		0
Transfers out of Level 3		0		0		0
Closing balance		69,998		69,998		63,268
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)		423		387		259
Bank Debt/Senior Secured Loans [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Net realized gain		0		0		0
Bank Debt/Senior Secured Loans [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Net realized gain		417		343		254
Preferred Equity [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		0		0
Total gains or losses included in earnings:
Purchase of investment securities		2,433	[1]	2,433	[2]
Proceeds from dispositions of investment securities		0		0
Transfers into Level 3		0		0
Transfers out of Level 3		0		0
Closing balance		2,563		2,563		0
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)		130		130
Preferred Equity [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Net realized gain		0		0
Preferred Equity [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Net realized gain		130		130
Common Equity/Warrants [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		13		6
Total gains or losses included in earnings:
Purchase of investment securities		30	[1]	32	[2]
Proceeds from dispositions of investment securities		(40)		(40)
Transfers into Level 3		0		0
Transfers out of Level 3		0		0
Closing balance		60		60		6
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)		51		56
Common Equity/Warrants [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Net realized gain		6		6
Common Equity/Warrants [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Net realized gain		$ 51		56
Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				$ 6		11
Total gains or losses included in earnings:
Purchase of investment securities	[3]					15
Proceeds from dispositions of investment securities						(5)
Transfers into Level 3						0
Transfers out of Level 3						0
Closing balance						6
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
Net change in unrealized gain (loss)						(18)
Warrant [Member] | Realized Investment Gains Losses [Member]
Total gains or losses included in earnings:
Net realized gain						0
Warrant [Member] | Unrealized Gain Loss On Investments [Member]
Total gains or losses included in earnings:
Net realized gain						$ (15)
[1] Includes PIK capitalization and accretion of discount Includes PIK capitalization and accretion of discount Includes PIK capitalization and accretion of discount

Fair Value - Summary of Company

Fair Value - Summary of Company's Level 3 (Detail) - Fair Value, Recurring [Member] $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 72,622	$ 63,275
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	72,621	63,274
Bank Debt/Senior Secured Loans [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	69,998	63,268
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 69,998	$ 63,268
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset	Asset
Investments, Fair Value Disclosure	$ 69,998	$ 63,268
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	9.7	10.6
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	16	17.6
Bank Debt/Senior Secured Loans [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	11.7	13
Preferred Equity [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 2,563
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investments, Fair Value Disclosure	$ 2,563
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset
Investments, Fair Value Disclosure	$ 2,563
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	9
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	9
Preferred Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Market Yield [Member] | Valuation, Income Approach [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Trading, Measurement Input	9
Common Equity [Member] | Fair Value, Inputs, Level 3 [Member] | Valuation, Transaction Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset
Investments, Fair Value Disclosure	$ 58
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Asset or Liability	Asset	Asset
Investments, Fair Value Disclosure	$ 2	$ 6
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	18.3	18.9
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	18.3	18.9
Warrant [Member] | Fair Value, Inputs, Level 3 [Member] | Measurement Input, Price Volatility [Member] | Valuation, Market Approach [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	18.3	18.9

Fair Value - Summary of Compa_2

Fair Value - Summary of Company's Level 3 (Parenthetical) (Detail)	Sep. 30, 2024 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Price paid to stockholders	$ 2.18

Fair Value - Additional Informa

Fair Value - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
SPV Facility [Member]
Fair Value [Line Items]
Debt instrument carrying amount		$ 24,210
Line of credit facility, Fair value of amount outstanding	$ 25,980
Subscription Facility [Member]
Fair Value [Line Items]
Debt instrument carrying amount	22,700	$ 17,550
Line of credit facility, Fair value of amount outstanding	$ 22,700

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Jan. 23, 2024	May 30, 2023	Feb. 18, 2022	Mar. 19, 2021
Line of Credit Facility [Line Items]
Long-Term Debt, Weighted Average Interest Rate, over Time	8.50%	8.11%
Line of credit facility, maximum amount outstanding during period	$ 49,430	$ 44,010
SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 35,000
Long-Term Debt, Gross		24,210
Subscription Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt, Gross	$ 22,700	$ 17,550
JPMorgan Chase Bank, N.A. [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Expiration Date	Feb. 18, 2027
Fee on undrawn commitments	0.875%
Line of Credit Facility, Collateral	The SPV Facility is secured by all of the assets held by the SPV.
Long-Term Debt, Gross	$ 25,980
JPMorgan Chase Bank, N.A. [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	3.07%
Debt Instrument, Description of Variable Rate Basis	Term SOFR
Debt Instrument, Description Of Floor Requirement	no SOFR
JPMorgan Chase Bank, N.A. [Member] | Maximum [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity				$ 75,000
JPMorgan Chase Bank, N.A. [Member] | Minimum [Member] | SPV Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity					$ 50,000
ING Capital LLC [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity						$ 25,000
Line of Credit Facility, Expiration Date	Mar. 14, 2025
ING Capital LLC [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Description of Variable Rate Basis	SOFR
ING Capital LLC [Member] | Maximum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	3%
ING Capital LLC [Member] | Minimum [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | Subscription Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	2.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Unfunded Commitments	$ 8,128	$ 11,545

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Unfunded Commitments (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	$ 8,128	$ 11,545
AAH Topco, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	1,301	2,262
OIS Management Services, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	1,166	1,710
CVAUSA Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	1,059	1,059
Arcutis Biotherapeutics, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	837	0
Western Veterinary Partners LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	674	0
Eyesouth Eye Care Holdco LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	649	343
SPR Therapeutics, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	626	0
FE Advance, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	451	0
Southern Orthodontic Partners Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	391	1,347
United Digestive MSO Parent, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	365	391
Medrina, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	239	239
Urology Management Holdings, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	172	151
Exactcare Parent, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	102	102
WCI-BXC Purchaser, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	96	96
Ardelyx, Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	1,345
Retina Midco, Inc. [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	966
Orthopedic Care Partners Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	901
Vertos Medical Inc [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	283
UVP Management, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	0	218
SunMed Group Holdings, LLC [Member]
Summary Of Unfunded Commitments [Line Items]
Unfunded Commitments	$ 0	$ 132

Unitholders' Capital - Summary

Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) - shares		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Equity [Abstract]
Units at beginning of period		1,185,276	1,069,642	1,069,642	888,565
Units issued		0	0	115,634	181,077
Units outstanding at end of period	[1],[2]	1,185,276	1,069,642	1,185,276	1,069,642
[1] Calculated as the change in net asset value (“NAV”) per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. Not annualized for periods less than one year.

Financial Highlights - Summary

Financial Highlights - Summary of Financial Highlights (Detail) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
		Sep. 30, 2024		Sep. 30, 2023		Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Investment Company, Financial Highlights [Line Items]
Net asset value per unit, beginning of period	[1]	$ 21.47		$ 21.77
Net investment income	[1]	1.68		0.95
Net realized and unrealized gain (loss)		0.45	[1],[2]	0.24
Investment Company, Investment Income (Loss) from Operations, Per Share, Total	[1]	2.13		1.19
From distributable earnings	[1]	(1.57)		(1.4)
Net asset value per unit, end of period	[1]	$ 22.03		$ 21.56
Total Return	[3],[4]	9.92%		5.47%
Unitholders' capital, end of period		$ 26,117	[3],[4]	$ 23,065	[3],[4]		$ 22,969
Units outstanding, end of period		1,185,276	[3],[4]	1,069,642	[3],[4]	1,185,276	1,069,642	1,069,642	888,565
Ratios to average net assets of Unitholders' Capital (c):
Net investment income	[4]	7.74%		4.35%
Operating expenses	[4]	6.04%		4.50%
Interest and other credit facility expenses	[4]	13.40%		12.83%
Total expenses	[4]	19.44%		17.33%
Average debt outstanding	[4]	$ 43,867		$ 30,079
Portfolio turnover ratio	[4]	13.30%		11.10%
[1] Calculated using the average units outstanding method. Weighted average units outstanding for the nine months ended September 30, 2024 and September 30, 2023 were 1,113,111 and 1,015,916 , respectively. Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end. Calculated as the change in net asset value (“NAV”) per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. Not annualized for periods less than one year.

Financial Highlights - Summar_2

Financial Highlights - Summary of Financial Highlights (Parenthetical) (Detail) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Investment Company, Financial Highlights [Abstract]
Weighted average number of units outstanding	1,113,111	1,015,916